Epigenetic mechanisms underlying metabolic-inflammatory diseases - Eckardt Treuter
The research of Eckardt Treuter's group attempts to better understand how the epigenome controls metabolic and inflammatory pathways in the context of obesity, type 2 diabetes, fatty liver disease and atherosclerosis. Epigenetic alterations that trigger changes in epigenome activity and gene expression are fundamental reprogramming events that contribute to the development of these diseases.
Epigenetic control of metabolism and inflammation by corepressors
Epigenetic control of metabolism and inflammation by corepressors
Epigenetic alterations that trigger changes in epigenome activity and gene expression are associated with the development of these diseases. However, the underlying regulatory mechanisms, the critical components involved, and the causal relationship of these associations are currently poorly defined. We address these issues with an emphasis on coregulators, proteins that modify chromatin and cooperate with transcription factors.
Liver and monocyte remodelling in non-alcoholic fatty liver disease and cardiovascular disease
Liver and monocyte remodelling in non-alcoholic fatty liver disease and cardiovascular disease
Activation of monocytes by pathological factors (i.e. obesity, hypercholesterolemia and hyperglycemia) serves as the key mechanism to promote the development of non-alcoholic fatty liver disease (NAFLD) and cardiovascular diseases (CVD). In collaboration with the clinical researchers we are trying to understand how an excess of lipids in the circulation alters the monocyte epigenome, particularly at enhancer regions, and modulates their metabolic activation, memory and atherogenic properties.
Selected publications
Selected publications
Here you can find some of our selected publications.